- Home
- ENTA vs BVFL Comparison
ENTA vs BVFL Comparison
Compare ENTA & BVFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- BVFL
- Stock Information
- Founded
- ENTA 1995
- BVFL 1873
- Country
- ENTA United States
- BVFL United States
- Employees
- ENTA N/A
- BVFL N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- BVFL Savings Institutions
- Sector
- ENTA Health Care
- BVFL Finance
- Exchange
- ENTA Nasdaq
- BVFL Nasdaq
- Market Cap
- ENTA 164.6M
- BVFL 163.3M
- IPO Year
- ENTA 2013
- BVFL N/A
- Fundamental
- Price
- ENTA $11.81
- BVFL $16.19
- Analyst Decision
- ENTA Strong Buy
- BVFL
- Analyst Count
- ENTA 5
- BVFL 0
- Target Price
- ENTA $20.20
- BVFL N/A
- AVG Volume (30 Days)
- ENTA 1.1M
- BVFL 32.6K
- Earning Date
- ENTA 08-11-2025
- BVFL 10-20-2025
- Dividend Yield
- ENTA N/A
- BVFL N/A
- EPS Growth
- ENTA N/A
- BVFL 27.09
- EPS
- ENTA N/A
- BVFL 1.07
- Revenue
- ENTA $64,806,000.00
- BVFL $38,333,000.00
- Revenue This Year
- ENTA N/A
- BVFL N/A
- Revenue Next Year
- ENTA $1.65
- BVFL N/A
- P/E Ratio
- ENTA N/A
- BVFL $15.30
- Revenue Growth
- ENTA N/A
- BVFL 2.48
- 52 Week Low
- ENTA $4.09
- BVFL $13.53
- 52 Week High
- ENTA $15.28
- BVFL $18.19
- Technical
- Relative Strength Index (RSI)
- ENTA 61.09
- BVFL 39.03
- Support Level
- ENTA $7.05
- BVFL $16.45
- Resistance Level
- ENTA $15.34
- BVFL $16.83
- Average True Range (ATR)
- ENTA 1.32
- BVFL 0.24
- MACD
- ENTA 0.47
- BVFL -0.08
- Stochastic Oscillator
- ENTA 53.86
- BVFL 11.76
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.